New ASCO 2021 poster highlights HPV-SEQ test’s ultra-sensitive detection of HPV 16/18 in plasma
Download our new poster, presented at the recent ASCO 2021 Annual Meeting: “Ultra-sensitive detection and…
Resources
Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ cfHPV-DNA assay, is highly effective for measuring HPV DNA in the plasma of patients with OPSCC enrolled in the OPTIMA 2 treatment de-escalation trial.
Baltimore, MD, 2021.06.02 – Sysmex Inostics, Inc., a global leader in the liquid biopsy revolution…
Sysmex Inostics Presents SafeSEQ NGS Data at AACR for NSCLC Patients
Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to…
Sysmex Inostics Presents Data Demonstrating Exquisite Sensitivity of SafeSEQ NGS Detection of MRD AML at ASH Annual Meeting
Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity…
Sysmex Inostics’ Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Baltimore, MD, 2020.09.08 – Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating…
Sysmex Inostics’ OncoBEAM™ RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Baltimore, Maryland, 2020.08.27 – Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor…
Sysmex Corporation received Insurance Coverage in Japan for Liquid Biopsy RAS Gene Mutation Testing for CRC Using High-Sensitivity Digital PCR
Kobe, Japan, 2020.08.03 – Sysmex Corporation (Chairman and CEO: Hisashi letsugu) announced today that it…
Sysmex Inostics’ Colorectal Cancer Blood-Based OncoBEAM™ RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Baltimore, Maryland, 2020.08.05 – Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating…
Sysmex Inostics and Oxford Gene Technology plasma and tissue sequencing demonstrate clearance of ctDNA correlates w/ pathologic complete response in breast cancer patients during neoadjuvant treatment
Hamburg, Germany and Baltimore, Maryland, 2020.01.28 Pathologist Dr. Vincente Peg of the Vall d´Hebron University…
Sysmex Inostics Tissue-independent Liquid Biopsy for Early Stage Breast Cancer Mutation Characterization and Monitoring Using Ultra-sensitive SafeSEQ Technology
HAMBURG, Germany and BALTIMORE, Dec. 16, 2019 /PRNewswire/ — New data presented by Dr. Ben…
High tissue biopsy to liquid biopsy concordance with OncoBEAM enhanced digital PCR – Part III
A recent publication summarizes the results of RAS mutation status in colorectal cancer (CRC) from…
Sysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development
Hamburg, Germany and Baltimore, Maryland, 2019.09.27 – Sysmex Inostics announces the availability of the SafeSEQ…